US-based medical research company Novocell changes its name to ViaCyte after raised more than $80m, including from Johnson & Johnson's corporate venturing unit.
US-based medical research company Novocell changes its name to ViaCyte after raised more than $80m, including from Johnson & Johnson’s corporate venturing unit.
ViaCyte last raised $25m in a series C round in 2007 from Johnson & Johnson Development Corporation, and venture capital firms Asset Management Company, Pacific Horizon Ventures and Sanderling Ventures.
